Search clinical trials for: Linagliptin 5mg

Total 12955 results

Merck Sharp & Dohme LLC

Completed

Initial Combination With Pioglitazone Study (0431-064)

Type 2 Diabetes Mellitus
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
Eisai Co., Ltd.

Completed

A Single-dose Study in Healthy Japanese Male Adults to Evaluate Pharmacokinetics and Pharmacodynamics of E5501 5 mg Tablet (Study E5501-J081-015)

Healthy

Japan
The Affiliated Hospital of Qingdao University

Completed

Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects

Healthy Subjects

China
Rabin Medical Center

Terminated

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19

Glucose Metabolism Disorders | Respiratory Tract Diseases | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | COVID 19 | Coronavirus | Metabolic Disease | Severe Acute Respiratory Syndrome Coronavirus 2 | Sars-CoV2 | Hormones | Hypoglycemic Agents | Incretins | Dipeptidyl-Peptidase IV Inhibitors and other conditions

Israel
Institute for Clinical Effectiveness, Japan

Completed

Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial (REASON)

Coronary Disease | Diabetes Mellitus | Dipeptidyl-Peptidase 4 Inhibitors | LDL Cholesterol | Glycosylated Hemoglobin

Japan
Evidem Consultores SL
Boehringer Ingelheim; Merck Serono International SA; European Commission

Unknown

Prevention of Microvascular Complications in Prediabetes e-PREDICE Study (ePREDICE)

PreDiabetes

Spain
Boehringer Ingelheim

Completed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function

Renal Insufficiency
Boehringer Ingelheim

Completed

Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid

Diabetes Mellitus, Type 2

Canada, Croatia, Estonia, France, Germany, India, Lithuania, Mexico, Netherlands, Romania, Russian Federation, Sweden, Tunisia, Ukraine
LG Life Sciences

Completed

Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Korea, Republic of
Boehringer Ingelheim

Completed

Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

Healthy

Germany
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Not yet recruiting

A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
Boryung Pharmaceutical Co., Ltd

Completed

A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers

Hypertension | Diabetes

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

Diabetes Mellitus, Type 2

Bangladesh, Belgium, Canada, China, Germany, Guatemala, Hong Kong, India, Lebanon, Mexico, Peru, Philippines, Spain, Taiwan
Genuine Research Center, Egypt
Eva Pharma

Completed

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

Healthy

Egypt
Boehringer Ingelheim

Completed

Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components

Healthy

Germany
Alexandria University

Recruiting

Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome

Polycystic Ovary Syndrome (PCOS)

Egypt
Bio-innova Co., Ltd

Not yet recruiting

Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator

Healthy Subjects
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin

Diabetes Mellitus, Type 2

United States
Merck Sharp & Dohme LLC

Completed

Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)
Boehringer Ingelheim

Completed

Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes

Diabetes Mellitus, Type 2

Belgium, Canada, France, India, Italy, Korea, Republic of, Malaysia, Netherlands, Spain
Yuhan Corporation

Completed

Phase 1/2a Trial of YH12852 in Healthy Subjects and Patients With Functional Constipation

Functional Constipation

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)

Diabetes Mellitus, Type 2
Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults

Solid Tumor | Idiopathic Pulmonary Fibrosis(IPF)

China
Korea University Anam Hospital

Completed

The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects

Diabetes Mellitus

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Healthy

Germany
Pfizer

Completed

Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691

Hepatitis C Virus

United States
Boehringer Ingelheim

Completed

Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin Tablet

Diabetes Mellitus, Type 2

Canada
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Unknown

Effect of Low Dose Combination of Linagliptin + Metformin to Prevent Diabetes

Insulin Resistance | Prediabetic State

Mexico
Boryung Pharmaceutical Co., Ltd

Completed

A Clinical Trial to Evaluate Pharmacokinetic Interactions and Safety Between Fimasartan and Linagliptin in Healthy Male Volunteers

Hypertension

Korea, Republic of
Boehringer Ingelheim

Completed

Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin

Healthy

China
Pfizer

Completed

Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States, Hungary, Taiwan, Romania, India, South Africa, Philippines, Slovakia
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Australia, Brazil, Canada, El Salvador, France, Korea, Republic of, New Zealand, Norway, Spain, Taiwan
Boehringer Ingelheim

Completed

Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers

Healthy

Germany
Hangzhou Grand Biologic Pharmaceutical, Inc.
Peking Union Medical College Hospital

Unknown

Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of of HZBio1 in Healthy Subjects

Healthy Participants

China
Medanta, The Medicity, India

Not yet recruiting

Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus (EmLina Renal)

Diabetes Mellitus | Kidney Transplant; Complications
Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Recruiting

Phase 1 Study of KH607 Tablets

Healthy

China
Targacept Inc.

Completed

Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
Sihuan Pharmaceutical Holdings Group Ltd.

Unknown

Janagliflozin Treat T2DM Monotherapy

Diabetes Type 2

China
EMS

Withdrawn

Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.

Type2 Diabetes Mellitus
Boehringer Ingelheim
Eli Lilly and Company

Completed

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Taiwan, Philippines, Australia, Hong Kong, Korea, Republic of, Canada, Italy, Malaysia, United Kingdom, Mexico, Greece, Spain, Netherlands, Switzerland, Israel, Portugal, Germany, Finland, Norway, Romania, Sweden, Serbia and more
Mackay Memorial Hospital

Unknown

The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin

Type2 Diabetes

Taiwan
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes

Type 2 Diabetes

China
Mitsubishi Tanabe Pharma America Inc.

Completed

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

Menopause Hot Flashes

United States
Amsterdam UMC, location VUmc

Completed

Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes (RENALIS)

Type 2 Diabetes

Netherlands
The Affiliated Hospital of Qingdao University

Completed

Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects

Healthy

China
Rabin Medical Center

Unknown

Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine Department

DM2
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)

Type 2 Diabetes Mellitus
Emory University
Merck Sharp & Dohme LLC

Terminated

DPP-4 Inhibition and TZD for DM Prevention (DInT DM)

Prediabetic State

United States
vTv Therapeutics

Completed

Add Glucokinase Activator to Target A1c (AGATA)

Diabetes Mellitus, Type 2

United States

3

Subscribe